AAHI NEWS
Innovations • Global Impact • In The News • Our People
AAHI's Approach to Next-Generation COVID Vaccines
Our unique immune-enhancing adjuvant and RNA platform technologies are supporting Covid vaccines for longer lasting, broadly protective immunity that can be given by nasal spray to prevent continued transmission.
INNOVATIONS
The latest scientific breakthroughs at AAHI.
A Universal Coronavirus Vaccine Candidate
A new preclinical study published in Nature Communications demonstrated that Duek Human Vaccine Institute's ferritin nanoparticle antigen combined with AAHI's 3M-052-AF adjuvant formulation protected non-human primates against SARS-CoV-2 variants of concern and psuedoviruses of SARS-CoV, including bat coronavirus - critical to protect against future animal-to-human spillover events.
Nasal Spray Vaccine Mechanisms of Delivery Require Meticulous Analysis
The spray pattern, plume geometry, and droplet size of a novel Amebiasis vaccine candidate were evaluated in models of the nasal cavity and lungs of both adjults and children. The research published in the International Journal of Pharmaceutics, paves the way for other nasal spray vaccines to elicit safe and strong mucosal immunity, including for high-risk populations such as children. Nasal spray vaccines also provide practical benefits of needless delivery. A vaccine against Amebiasis, a common infectious disease in tropical areas that causes 55,000 deaths per year, does not yet exist.
One Step Closer to an HIV Vaccine
Researcher's at Duke Human Vaccine Institute evaluated their novel HIV envelope protein antigen formulated with AAHI's 3M-052-SE adjuvant formulation and found that the vaccine candidate protects primates who are exposed to the virus. The study was recently published in Science Translational Medicine.
Make your products accessible to those who need them most. Collaborate with AAHI.
GLOBAL IMPACT
NOVEMBER 2022
Collaboration across communities. Explore AAHI's different areas of impact.
San Antonio, USA
Diversifying the Next Generation of Tuberculosis Vaccines
AAHI partners with Texas Biomed to explore novel adjuvant technology, mix-and-match protein and RNA vaccine regimens, and nasal spray vaccines to protect against TB using preclinical models designed to reflect the genetic diversity in the human population.
Bangkok, Thailand
Phase 1 Clinical Trial of Adjuvanted Plant Based Protein COVID-19 Vaccine
Baiya Phytopharm announces preliminary results of trials showing its plant-based SARS-CoV-2 vaccine candidate containing AAHI's 3M-052-AF/Alum adjuvant formulation is safe in humans.
Seattle, USA
Adjuvanted HIV Vaccine Clinically Evaluated with New Germline-Targeting Approach
A new germline-targeting antigen is expected to elicit a particular class of broadly neutralizing antibodies that protect from viral mutations when paired with AAHI's 3M-052-AF adjuvant formulation. Phase 1 clinical trials commenced over the summer in our own backyard.
Help us make impossible vaccines possible.
IN THE NEWS
By Allison Gatlin
Investor's Business Daily
"The virus always wins. The virus is always a few steps ahead of us. Any vaccine strategy that requires us to catch up means we're always going to be behind," Dr. Corey Casper, Chief Executive Officer, shares his thoughts about developing viral threats. He highlights the importance of continued investment in the development of a next-generation vaccine that can protect against all coronaviruses - a "pan" vaccine.
By Gail Dutton
Genetic Engineering & Biotechnology News
AAHI's Senior Vice President, Formulations, Christopher Fox, PhD, discusses several approaches to simplifying manufacturing processes for RNA and protein vaccines and enable equitable access to life-saving health solutions in low- and middle-income countries.
OUR PEOPLE
Collaboration across communities. Explore our different areas of impact.
Featured Post
November 8-10 | Boston Park Plaza Hotel
AAHI's scientists are presenting novel applications of our RNA vaccine platform at the 10th International mRNA Conference, a premier meeting for industry and academic professionals to explore the rapidly advancing science and business of mRNA medicines.
Openings and Opportunities
Research
The Senior Scientist joining our RNA vaccine team will be responsible for broadening the applications of
AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets.
Operations/Project Management
The Sponsored Research Administrator will provide sponsored support for research awards, product development contracts, and other funded projects while also playing a key role in the creation, budgeting, and submission of grant and contract applications.
Learn more about our formulation technology
We partner with biotech leaders to develop vaccines and more.
Synthetic TLR4 ligand in squalene nanoemulsion
Synthetic TLR4 ligand in QS- 21 containing liposome
Synthetic TLR4 ligand in aqueous formulation
Dual agonist containing both TLR4 and TLR7/8 ligands
Synthetic TLR7/8 ligand in
squalene nanoemulsion
Synthetic TLR7/8 ligand
adsorbed to aluminum
Synthetic TLR7/8 ligand in
aqueous formulation
Nanostructured lipid carrier
See how our formulations are being used.
Follow AAHI
Sign up to stay in touch!
Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.